HOMBACH ROBERT J. 4

What Happened

• Robert J. Hombach, a director of Seaport Therapeutics (SPTX), acquired 13,000 shares on 2026-06-22 in an open-market purchase (transaction code P). The reported weighted average price was $18.14 per share, for a total reported cost of $235,768. This was a purchase rather than a sale.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely filing).
• Price: weighted average $18.14; reported purchase price range $17.65–$18.27 (per footnote).
• Shares acquired: 13,000; total value reported: $235,768.
• Shares owned after transaction: not disclosed in the provided Form 4 excerpt.
• Footnotes: F1 notes the weighted-average price and the underlying per-share price range; F2 states the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
• No indication of a 10b5-1 plan, tax withholding, gift, or derivative exercise in this filing.

Context

• Insider purchases are often noted by investors as a potential signal of confidence, but they are one data point and not a guarantee of future stock performance. This filing documents a straightforward open-market purchase by a company director and was filed promptly with the SEC.